Relay Therapeutics, Inc. Increase (Decrease) in Other Operating Liabilities
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Other Operating Liabilities of $789.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-06
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $405.00K.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $384.00K.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$615.00K, a 197.00% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $469.00K, a 20.24% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was -$1.53M, a 294.27% decline from fiscal 2024.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $786.00K.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2023 was -$24.95M, a 331.94% decline from fiscal 2022.
- Relay Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2022 was $10.76M, a 28.29% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $789.00K 10-Q · filed 2026-08-06 | $174.00K derived: sum of 3 quarters · filed 2026-08-06 | $643.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $384.00K 10-Q · filed 2026-05-05 | -$231.00K derived: sum of 2 quarters · filed 2026-05-05 | $238.00K derived: sum of 3 quarters · filed 2026-05-05 | -$835.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$146.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.22M derived: sum of 3 quarters · filed 2026-08-06 | -$1.53M 10-K · filed 2026-02-26 |
| 2025-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$604.00K derived: sum of 2 quarters · filed 2026-08-06 | -$912.00K 10-Q · filed 2025-11-06 | -$278.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.38M 10-Q · filed 2026-08-06 | -$747.00K derived: sum of 3 quarters · filed 2026-08-06 | -$159.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$308.00K 10-Q · filed 2026-05-05 | $326.00K derived: sum of 2 quarters · filed 2026-05-05 | $914.00K derived: sum of 3 quarters · filed 2026-05-05 | $20.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.22M derived: sum of 2 quarters · filed 2026-02-26 | $328.00K derived: sum of 3 quarters · filed 2026-02-26 | $786.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $588.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$306.00K derived: sum of 2 quarters · filed 2025-11-06 | $152.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$894.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$436.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $458.00K 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | -$24.95M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $10.76M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $15.00M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |